PMID-sentid	Pub_year	Sent_text	compound_name	comp_offset	prot_official_name	organism	prot_offset
17141810-3	2007	Subcutaneous injection of mCPP (1 and 3mg/kg) and the preferential 5-HT(2C) receptor agonist MK212 (0.7 and 1mg/kg) induced hypolocomotion during novelty exposure.	6-chloro-2-(1-piperazinyl)pyrazine	93-98	5-hydroxytryptamine (serotonin) receptor 2C	Mus musculus	67-84
21118683-3	2011	In the 5-HT(2A) mice, the preferential 5-HT(2A) receptor agonist DOI (2.5mg/kg, s.c.) induced a slight but significant increase in cortical dopamine efflux only in the wild type (WT) mice; MK-212 (2.5mg/kg) reduced dopamine efflux in both WT and receptor knockout (KO) mice; moreover, MCPP, 2.5mg/kg, had no effect in either types.	6-chloro-2-(1-piperazinyl)pyrazine	189-195	5-hydroxytryptamine (serotonin) receptor 2A	Mus musculus	39-56
20850460-4	2011	Our results showed that intra-dPAG microinjection of the endogenous agonist 5-HT (20 nmol) or the 5-HT2C receptor agonists MK-212 (1 and 10 nmol) and RO-600175 (40 nmol) significantly increased inhibitory avoidance acquisition in rats tested in the elevated T-maze, suggesting an anxiogenic effect.	6-chloro-2-(1-piperazinyl)pyrazine	123-129	5-hydroxytryptamine receptor 2C	Rattus norvegicus	98-104
20850460-7	2011	The behavioral effects caused by 5-HT and MK-212 were fully blocked by previous local microinjection of the 5-HT2C receptor antagonist SB-242084.	6-chloro-2-(1-piperazinyl)pyrazine	42-48	5-hydroxytryptamine receptor 2C	Rattus norvegicus	108-114
17141810-5	2007	In contrast, MK212 induced hypolocomotion that was blocked by SB242084, indicating a specific 5-HT(2C) receptor involvement.	6-chloro-2-(1-piperazinyl)pyrazine	13-18	5-hydroxytryptamine (serotonin) receptor 2C	Mus musculus	94-111
20542064-8	2010	The hyperactivity induced by L-DOPA and NSD1015 was reduced by the alpha(2C) antagonist rauwolscine (1 mg/kg) and the 5-HT(2C) agonist MK212 (5 mg/kg), but not by the D2 dopamine receptor antagonist remoxipride (3 mg/kg) or the D1 dopamine receptor antagonist SCH23390 (1 mg/kg).	6-chloro-2-(1-piperazinyl)pyrazine	135-140	dopamine receptor D2	Rattus norvegicus	167-187
17415471-1	2006	A dose-dependent the effect of 5HT2C-receptor agonist MK-212 on mouse behavior was demonstrated.	6-chloro-2-(1-piperazinyl)pyrazine	54-60	5-hydroxytryptamine (serotonin) receptor 2C	Mus musculus	31-45
1664500-6	1991	Administration of the 5-HT1/5-HT2 agonist MK-212 produced an elevation in both plasma alpha-MSH and beta-endorphin levels.	6-chloro-2-(1-piperazinyl)pyrazine	42-48	proopiomelanocortin	Rattus norvegicus	86-95
8891601-0	1996	Involvement of 5-HT2A receptors in the elevation of rat serum corticosterone concentrations by quipazine and MK-212.	6-chloro-2-(1-piperazinyl)pyrazine	109-115	5-hydroxytryptamine receptor 2A	Rattus norvegicus	15-21
7495925-0	1995	Effect of pindolol pretreatment on MK-212-induced plasma cortisol and prolactin responses in normal men.	6-chloro-2-(1-piperazinyl)pyrazine	35-41	prolactin	Homo sapiens	70-79
8149973-2	1994	Both the mixed 5-HT2/5-HT1C receptor agonist, 1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane (DOI), and the preferential 5-HT1C agonist, 2-chloro-6-(1-piperazinyl)pyrazine monohydrochloride (MK-212), elicited a significant increase in plasma prolactin concentration with DOI about 20 times more potent than MK-212.	6-chloro-2-(1-piperazinyl)pyrazine	190-196	5-hydroxytryptamine receptor 2C	Rattus norvegicus	120-126
8149973-2	1994	Both the mixed 5-HT2/5-HT1C receptor agonist, 1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane (DOI), and the preferential 5-HT1C agonist, 2-chloro-6-(1-piperazinyl)pyrazine monohydrochloride (MK-212), elicited a significant increase in plasma prolactin concentration with DOI about 20 times more potent than MK-212.	6-chloro-2-(1-piperazinyl)pyrazine	306-312	5-hydroxytryptamine receptor 2C	Rattus norvegicus	120-126
8394920-10	1993	Only MK-212 increased vasopressin levels and this effect was potentiated by fluoxetine, but not by DMI.	6-chloro-2-(1-piperazinyl)pyrazine	5-11	arginine vasopressin	Homo sapiens	22-33
16517693-4	2006	5-HT2C receptor agonists m-chlorophenylpiperazine and MK-212 [6-chloro-2-(1-piperaxinyl)pyrazine] were weak agonists in these cells, with potencies of 110 and 880 nM, respectively.	6-chloro-2-(1-piperazinyl)pyrazine	54-60	5-hydroxytryptamine receptor 2C	Homo sapiens	0-6
16521035-6	2006	The selective 5-HT2C agonist MK-212 mimicked the anxiogenic response of fluoxetine.	6-chloro-2-(1-piperazinyl)pyrazine	29-35	5-hydroxytryptamine receptor 2C	Rattus norvegicus	14-20
11103887-4	2000	MK212 (a mixed 5-HT2C/A agonist) induced partial substitution that was antagonized by SB242084, but not by MDL100907.	6-chloro-2-(1-piperazinyl)pyrazine	0-5	5-hydroxytryptamine receptor 2C	Homo sapiens	15-21
10498829-11	1999	Piperazines such as m-Chlorophenylpiperazine (mCPP), ORG-12962, MK-212 and also ORG-37684 exhibited a rank order of potency of 5-HT2C>5-HT2B>5-HT2A.	6-chloro-2-(1-piperazinyl)pyrazine	64-70	5-hydroxytryptamine receptor 2C	Homo sapiens	127-133
10498829-11	1999	Piperazines such as m-Chlorophenylpiperazine (mCPP), ORG-12962, MK-212 and also ORG-37684 exhibited a rank order of potency of 5-HT2C>5-HT2B>5-HT2A.	6-chloro-2-(1-piperazinyl)pyrazine	64-70	5-hydroxytryptamine receptor 2B	Homo sapiens	137-143
10498829-11	1999	Piperazines such as m-Chlorophenylpiperazine (mCPP), ORG-12962, MK-212 and also ORG-37684 exhibited a rank order of potency of 5-HT2C>5-HT2B>5-HT2A.	6-chloro-2-(1-piperazinyl)pyrazine	64-70	5-hydroxytryptamine receptor 2A	Cricetulus griseus	147-153
10368872-4	1999	Significant ibogaine-appropriate responding was observed following treatment with the 5-HT2C agonists MK-212 (79.6%) and mCPP (76.4%).	6-chloro-2-(1-piperazinyl)pyrazine	102-108	5-hydroxytryptamine receptor 2C	Rattus norvegicus	86-92
7495925-3	1995	MK-212 induced a significant increase in plasma concentrations of cortisol and PRL.	6-chloro-2-(1-piperazinyl)pyrazine	0-6	prolactin	Homo sapiens	79-82
7495925-4	1995	The MK-212-induced response in plasma cortisol was not diminished by pindolol pretreatment, whereas the MK-212-induced PRL response was significantly inhibited by pindolol pretreatment.	6-chloro-2-(1-piperazinyl)pyrazine	104-110	prolactin	Homo sapiens	119-122
7495925-5	1995	These data suggest that the MK-212-induced cortisol response may be mediated by 5-HT2A or 5-HT2C receptor activation, or both, despite 5-HT1A inhibition; however, PRL secretion by MK-212 requires 5-HT1A receptor availability as well as 5-HT2A/5-HT2C receptor activation, since blockade of the former appears to blunt the PRL responses to MK-212.	6-chloro-2-(1-piperazinyl)pyrazine	28-34	5-hydroxytryptamine receptor 2A	Homo sapiens	80-86
7495925-5	1995	These data suggest that the MK-212-induced cortisol response may be mediated by 5-HT2A or 5-HT2C receptor activation, or both, despite 5-HT1A inhibition; however, PRL secretion by MK-212 requires 5-HT1A receptor availability as well as 5-HT2A/5-HT2C receptor activation, since blockade of the former appears to blunt the PRL responses to MK-212.	6-chloro-2-(1-piperazinyl)pyrazine	28-34	5-hydroxytryptamine receptor 1A	Homo sapiens	135-141
7495925-5	1995	These data suggest that the MK-212-induced cortisol response may be mediated by 5-HT2A or 5-HT2C receptor activation, or both, despite 5-HT1A inhibition; however, PRL secretion by MK-212 requires 5-HT1A receptor availability as well as 5-HT2A/5-HT2C receptor activation, since blockade of the former appears to blunt the PRL responses to MK-212.	6-chloro-2-(1-piperazinyl)pyrazine	28-34	prolactin	Homo sapiens	163-166
7495925-5	1995	These data suggest that the MK-212-induced cortisol response may be mediated by 5-HT2A or 5-HT2C receptor activation, or both, despite 5-HT1A inhibition; however, PRL secretion by MK-212 requires 5-HT1A receptor availability as well as 5-HT2A/5-HT2C receptor activation, since blockade of the former appears to blunt the PRL responses to MK-212.	6-chloro-2-(1-piperazinyl)pyrazine	28-34	5-hydroxytryptamine receptor 1A	Homo sapiens	196-211
7495925-5	1995	These data suggest that the MK-212-induced cortisol response may be mediated by 5-HT2A or 5-HT2C receptor activation, or both, despite 5-HT1A inhibition; however, PRL secretion by MK-212 requires 5-HT1A receptor availability as well as 5-HT2A/5-HT2C receptor activation, since blockade of the former appears to blunt the PRL responses to MK-212.	6-chloro-2-(1-piperazinyl)pyrazine	28-34	5-hydroxytryptamine receptor 2A	Homo sapiens	236-242
7495925-5	1995	These data suggest that the MK-212-induced cortisol response may be mediated by 5-HT2A or 5-HT2C receptor activation, or both, despite 5-HT1A inhibition; however, PRL secretion by MK-212 requires 5-HT1A receptor availability as well as 5-HT2A/5-HT2C receptor activation, since blockade of the former appears to blunt the PRL responses to MK-212.	6-chloro-2-(1-piperazinyl)pyrazine	28-34	prolactin	Homo sapiens	321-324
7495925-5	1995	These data suggest that the MK-212-induced cortisol response may be mediated by 5-HT2A or 5-HT2C receptor activation, or both, despite 5-HT1A inhibition; however, PRL secretion by MK-212 requires 5-HT1A receptor availability as well as 5-HT2A/5-HT2C receptor activation, since blockade of the former appears to blunt the PRL responses to MK-212.	6-chloro-2-(1-piperazinyl)pyrazine	180-186	prolactin	Homo sapiens	163-166
7495925-5	1995	These data suggest that the MK-212-induced cortisol response may be mediated by 5-HT2A or 5-HT2C receptor activation, or both, despite 5-HT1A inhibition; however, PRL secretion by MK-212 requires 5-HT1A receptor availability as well as 5-HT2A/5-HT2C receptor activation, since blockade of the former appears to blunt the PRL responses to MK-212.	6-chloro-2-(1-piperazinyl)pyrazine	180-186	prolactin	Homo sapiens	163-166
7956751-5	1994	However, the plasma cortisol and PRL responses to MK-212 did not differ between the two groups.	6-chloro-2-(1-piperazinyl)pyrazine	50-56	prolactin	Homo sapiens	33-36
1664500-8	1991	Pretreatment with the selective D2 dopamine agonist apomorphine blocked MK-212-induced release of alpha-MSH but not beta-endorphin.	6-chloro-2-(1-piperazinyl)pyrazine	72-78	proopiomelanocortin	Rattus norvegicus	98-107
1664500-9	1991	Our results show that manipulation of 5-HT synthesis/reuptake does not affect release of alpha-MSH, but that direct activation of 5-HT receptors with the nonselective agonist MK-212 stimulates alpha-MSH release.	6-chloro-2-(1-piperazinyl)pyrazine	175-181	proopiomelanocortin	Rattus norvegicus	193-202
1664500-10	1991	The ability of apomorphine to block MK-212-induced release of alpha-MSH suggests a direct antagonism between dopaminergic and serotonergic regulation of alpha-MSH release.	6-chloro-2-(1-piperazinyl)pyrazine	36-42	proopiomelanocortin	Rattus norvegicus	62-71
1664500-10	1991	The ability of apomorphine to block MK-212-induced release of alpha-MSH suggests a direct antagonism between dopaminergic and serotonergic regulation of alpha-MSH release.	6-chloro-2-(1-piperazinyl)pyrazine	36-42	proopiomelanocortin	Rattus norvegicus	153-162
2164094-5	1990	MK-212 and (+)LSD mimicked 5-HT, increasing transferrin levels to the same extent.	6-chloro-2-(1-piperazinyl)pyrazine	0-6	transferrin	Homo sapiens	44-55
2150180-9	1990	Forepaw treading in rats induced by the 5-HT1A-agonist 8-OH-DPAT was attenuated by the 5-HT1C-agonists MK 212 and mCPP.	6-chloro-2-(1-piperazinyl)pyrazine	103-109	5-hydroxytryptamine receptor 1A	Rattus norvegicus	40-46
2150180-9	1990	Forepaw treading in rats induced by the 5-HT1A-agonist 8-OH-DPAT was attenuated by the 5-HT1C-agonists MK 212 and mCPP.	6-chloro-2-(1-piperazinyl)pyrazine	103-109	5-hydroxytryptamine receptor 2C	Rattus norvegicus	87-93
1756196-4	1991	The plasma PRL, but not the plasma cortisol response, following MK-212 was also significantly lower in the alcoholics.	6-chloro-2-(1-piperazinyl)pyrazine	64-70	prolactin	Homo sapiens	11-14
2136566-2	1990	Male Wistar rats implanted with a cannula in the 3rd ventricle were injected with the 5-HT1C/5-HT2 agonist 6-chloro-2-[1-piperazinyl]-pyrazine (MK-212) at doses of 0.5, 5, 25, 50 and 125 nmol/2 microliters.	6-chloro-2-(1-piperazinyl)pyrazine	144-150	5-hydroxytryptamine receptor 2C	Rattus norvegicus	86-92
2101105-4	1990	The pretreatment of thyroidectomized rats with 6-chloro-2-[1-piperazinyl]- pyrazine (MK 212), a serotonin agonist that easily penetrates the blood-brain barrier, reversed the reduction in stress-induced prolactin release in the thyroidectomized group.	6-chloro-2-(1-piperazinyl)pyrazine	47-83	prolactin	Rattus norvegicus	203-212
2101105-4	1990	The pretreatment of thyroidectomized rats with 6-chloro-2-[1-piperazinyl]- pyrazine (MK 212), a serotonin agonist that easily penetrates the blood-brain barrier, reversed the reduction in stress-induced prolactin release in the thyroidectomized group.	6-chloro-2-(1-piperazinyl)pyrazine	85-91	prolactin	Rattus norvegicus	203-212
2136567-3	1990	MK-212 induced a significant reduction in the drinking response evoked by Ang II or carbachol which was more marked in the case of the cholinergic agonist.	6-chloro-2-(1-piperazinyl)pyrazine	0-6	angiotensinogen	Rattus norvegicus	74-80
34560172-4	2022	The results showed that systemic administration of the 5-HT2C receptor agonist MK212 did not affect normal PPI behavior, but reversed the PPI deficits induced by the N-methyl d-aspartate receptor antagonist MK801 in mice.	6-chloro-2-(1-piperazinyl)pyrazine	79-84	5-hydroxytryptamine (serotonin) receptor 2C	Mus musculus	55-70
2533356-5	1989	These data are consistent with other evidence that these physiological effects of 8-OH-DPAT and MK-212 are mediated by 5-HT1A and 5-HT2 receptors, respectively.	6-chloro-2-(1-piperazinyl)pyrazine	96-102	5-hydroxytryptamine receptor 1A	Homo sapiens	119-145
2562060-0	1989	MK-212 increases rat plasma ACTH concentration by activation of the 5-HT1C receptor subtype.	6-chloro-2-(1-piperazinyl)pyrazine	0-6	5-hydroxytryptamine receptor 2C	Rattus norvegicus	68-74
2562060-2	1989	MK-212 significantly increased plasma ACTH levels, and this effect was blocked by the 5-HT1C antagonists mesulergine and metergoline but not by spiperone, ketanserin, or (-)-pindolol.	6-chloro-2-(1-piperazinyl)pyrazine	0-6	5-hydroxytryptamine receptor 2C	Rattus norvegicus	86-92
2562060-3	1989	The results suggest that MK-212 activates the 5-HT1C receptor subtype to increase ACTH.	6-chloro-2-(1-piperazinyl)pyrazine	25-31	5-hydroxytryptamine receptor 2C	Rattus norvegicus	46-52
3374754-7	1988	However, treatment with MK212, a serotonin agonist with 5-HT1 + 5-HT2 activity, induced a significant increase in plasma vasopressin concentration.	6-chloro-2-(1-piperazinyl)pyrazine	24-29	arginine vasopressin	Rattus norvegicus	121-132
2565390-3	1989	However, pretreatment with GEP (10 mg/kg) or IPS (10 mg/kg) significantly attenuated the increase in serum PRL concentration elicited by the 5-HT agonists 5-methoxy-N,N-dimethyltryptamine or 6-chloro-2-(1-piperazinyl)-pyrazine (MK-212).	6-chloro-2-(1-piperazinyl)pyrazine	191-226	prolactin	Rattus norvegicus	107-110
2565390-3	1989	However, pretreatment with GEP (10 mg/kg) or IPS (10 mg/kg) significantly attenuated the increase in serum PRL concentration elicited by the 5-HT agonists 5-methoxy-N,N-dimethyltryptamine or 6-chloro-2-(1-piperazinyl)-pyrazine (MK-212).	6-chloro-2-(1-piperazinyl)pyrazine	228-234	prolactin	Rattus norvegicus	107-110
2524677-3	1989	The 5-HT1A + 5-HT1B agonist RU 24969 (5-methoxy-3[1,2,3,6-tetrahydropyridin-4-yl]-1H-indole succinate) and the 5-HT1 + 5-HT2 agonist MK-212 (6-chloro-2-[1-piperazinyl]pirazine) increased levels of prolactin in plasma in a dose-dependent manner.	6-chloro-2-(1-piperazinyl)pyrazine	133-139	5-hydroxytryptamine receptor 1A	Rattus norvegicus	4-10
3374754-8	1988	The effect of MK212 on plasma vasopressin was completely abolished by the selective 5-HT2 receptor blocker LY53857.	6-chloro-2-(1-piperazinyl)pyrazine	14-19	arginine vasopressin	Rattus norvegicus	30-41
31837357-13	2020	We also found that MUC13 was directly regulated by miR-212-3p, whose downregulation was related to aberrant CpG hypermethylation in the promoter area.	6-chloro-2-(1-piperazinyl)pyrazine	55-61	mucin 13, cell surface associated	Homo sapiens	19-24
32039486-0	2020	miR-212-5p exerts tumor promoter function by regulating the Id3/PI3K/Akt axis in lung adenocarcinoma cells.	6-chloro-2-(1-piperazinyl)pyrazine	4-10	inhibitor of DNA binding 3, HLH protein	Homo sapiens	60-63
32039486-0	2020	miR-212-5p exerts tumor promoter function by regulating the Id3/PI3K/Akt axis in lung adenocarcinoma cells.	6-chloro-2-(1-piperazinyl)pyrazine	4-10	AKT serine/threonine kinase 1	Homo sapiens	69-72
32039486-3	2020	We identified miR-212-5p as a negative posttranscriptional modulator of Id3.	6-chloro-2-(1-piperazinyl)pyrazine	18-24	inhibitor of DNA binding 3, HLH protein	Homo sapiens	72-75
32039486-4	2020	Dual luciferase reporter assay was used to verify that Id3 is a direct target gene of miR-212-5p.	6-chloro-2-(1-piperazinyl)pyrazine	90-96	inhibitor of DNA binding 3, HLH protein	Homo sapiens	55-58
32039486-7	2020	Besides this, miR-212-5p could directly target Id3 and reduce its expression.	6-chloro-2-(1-piperazinyl)pyrazine	18-24	inhibitor of DNA binding 3, HLH protein	Homo sapiens	47-50
32039486-8	2020	miR-212-5p overexpression significantly accelerated cell proliferation, migration, and invasion by reversing the effects of Id3.	6-chloro-2-(1-piperazinyl)pyrazine	4-10	inhibitor of DNA binding 3, HLH protein	Homo sapiens	124-127
32039486-9	2020	Id3 overexpression by silencing miR-212-5p expression suppressed phosphatidylinositol 3 kinase (PI3K)/Akt activity and consequently promoted apoptosis and inhibited cell proliferation in lung cancer cells.	6-chloro-2-(1-piperazinyl)pyrazine	36-42	inhibitor of DNA binding 3, HLH protein	Homo sapiens	0-3
32039486-9	2020	Id3 overexpression by silencing miR-212-5p expression suppressed phosphatidylinositol 3 kinase (PI3K)/Akt activity and consequently promoted apoptosis and inhibited cell proliferation in lung cancer cells.	6-chloro-2-(1-piperazinyl)pyrazine	36-42	phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta	Homo sapiens	65-94
32039486-9	2020	Id3 overexpression by silencing miR-212-5p expression suppressed phosphatidylinositol 3 kinase (PI3K)/Akt activity and consequently promoted apoptosis and inhibited cell proliferation in lung cancer cells.	6-chloro-2-(1-piperazinyl)pyrazine	36-42	AKT serine/threonine kinase 1	Homo sapiens	102-105
32039486-10	2020	Consistent with the in vitro results, a xenograft mouse model was used to validate the fact that miR-212-5p could promote tumorigenesis by targeting Id3 and activate the PI3K/Akt pathway in vivo as well.	6-chloro-2-(1-piperazinyl)pyrazine	101-107	inhibitor of DNA binding 3	Mus musculus	149-152
32039486-10	2020	Consistent with the in vitro results, a xenograft mouse model was used to validate the fact that miR-212-5p could promote tumorigenesis by targeting Id3 and activate the PI3K/Akt pathway in vivo as well.	6-chloro-2-(1-piperazinyl)pyrazine	101-107	thymoma viral proto-oncogene 1	Mus musculus	175-178
32039486-11	2020	Taken together, the present results indicated that miR-212-5p may be involved in progression of NSCLC through the PI3K/Akt signaling pathway by targeting Id3.	6-chloro-2-(1-piperazinyl)pyrazine	55-61	thymoma viral proto-oncogene 1	Mus musculus	119-122
32039486-11	2020	Taken together, the present results indicated that miR-212-5p may be involved in progression of NSCLC through the PI3K/Akt signaling pathway by targeting Id3.	6-chloro-2-(1-piperazinyl)pyrazine	55-61	inhibitor of DNA binding 3	Mus musculus	154-157
3365458-0	1988	Stimulation of serum cortisol and prolactin secretion in humans by MK-212, a centrally active serotonin agonist.	6-chloro-2-(1-piperazinyl)pyrazine	67-73	prolactin	Homo sapiens	34-43
3365458-5	1988	The cortisol and prolactin responses to the 40-mg dose of MK-212 were positively correlated (rho = + 0.85, p less than 0.02).	6-chloro-2-(1-piperazinyl)pyrazine	58-64	prolactin	Homo sapiens	17-26
3365458-8	1988	MK-212 may stimulate the secretion of cortisol and prolactin in humans via a serotonin (5-HT2) receptor mechanism and may be a valuable tool with which to study 5-HT receptor sensitivity in humans.	6-chloro-2-(1-piperazinyl)pyrazine	0-6	prolactin	Homo sapiens	51-60
2952898-14	1987	LY53857, furthermore, unmasked a renin-suppressive effect of MK-212, since injection of MK-212 (10.0 mg/kg, i.p.)	6-chloro-2-(1-piperazinyl)pyrazine	61-67	renin	Homo sapiens	33-38
31837357-14	2020	CONCLUSIONS: These findings suggest that aberrant hypermethylation-induced downregulation of miR-212-3p results in overexpression of MUC13 in iCCA, leading to metastasis via activation of the EGFR/PI3K/AKT signaling pathway.	6-chloro-2-(1-piperazinyl)pyrazine	97-103	mucin 13, cell surface associated	Homo sapiens	133-138
31837357-14	2020	CONCLUSIONS: These findings suggest that aberrant hypermethylation-induced downregulation of miR-212-3p results in overexpression of MUC13 in iCCA, leading to metastasis via activation of the EGFR/PI3K/AKT signaling pathway.	6-chloro-2-(1-piperazinyl)pyrazine	97-103	epidermal growth factor receptor	Homo sapiens	192-196
31837357-14	2020	CONCLUSIONS: These findings suggest that aberrant hypermethylation-induced downregulation of miR-212-3p results in overexpression of MUC13 in iCCA, leading to metastasis via activation of the EGFR/PI3K/AKT signaling pathway.	6-chloro-2-(1-piperazinyl)pyrazine	97-103	AKT serine/threonine kinase 1	Homo sapiens	202-205
31713483-0	2019	microRNA-212-3p attenuates neuropathic pain via targeting sodium voltage-gated channel alpha subunit 3 (NaV 1.3).	6-chloro-2-(1-piperazinyl)pyrazine	9-15	sodium voltage-gated channel alpha subunit 3	Rattus norvegicus	58-102
31968217-4	2020	In this study, we discovered that chronic alcohol treatment increased editing of RNA of 5-HT2CR via up-regulating the expression of ADAR2, consequently reducing the release of ATP from astrocytes induced by 5-HT2CR agonist, MK212.	6-chloro-2-(1-piperazinyl)pyrazine	224-229	5-hydroxytryptamine (serotonin) receptor 2C	Mus musculus	88-95
31968217-4	2020	In this study, we discovered that chronic alcohol treatment increased editing of RNA of 5-HT2CR via up-regulating the expression of ADAR2, consequently reducing the release of ATP from astrocytes induced by 5-HT2CR agonist, MK212.	6-chloro-2-(1-piperazinyl)pyrazine	224-229	adenosine deaminase, RNA-specific, B1	Mus musculus	132-137
31968217-4	2020	In this study, we discovered that chronic alcohol treatment increased editing of RNA of 5-HT2CR via up-regulating the expression of ADAR2, consequently reducing the release of ATP from astrocytes induced by 5-HT2CR agonist, MK212.	6-chloro-2-(1-piperazinyl)pyrazine	224-229	5-hydroxytryptamine (serotonin) receptor 2C	Mus musculus	207-214
31968217-6	2020	The increased release of astroglial ATP by MK212 which was suppressed by chronic alcohol consumption, and reduction in ADAR2 activity eliminated the RNA editing of 5-HT2CR increased by alcohol in vitro and recovered the release of ATP from astrocytes induced by MK212.	6-chloro-2-(1-piperazinyl)pyrazine	262-267	adenosine deaminase, RNA-specific, B1	Mus musculus	119-124
31968217-6	2020	The increased release of astroglial ATP by MK212 which was suppressed by chronic alcohol consumption, and reduction in ADAR2 activity eliminated the RNA editing of 5-HT2CR increased by alcohol in vitro and recovered the release of ATP from astrocytes induced by MK212.	6-chloro-2-(1-piperazinyl)pyrazine	262-267	5-hydroxytryptamine (serotonin) receptor 2C	Mus musculus	164-171
31914881-0	2020	LncRNA XIST serves as a ceRNA to regulate the expression of ASF1A, BRWD1M, and PFKFB2 in kidney transplant acute kidney injury via sponging hsa-miR-212-3p and hsa-miR-122-5p.	6-chloro-2-(1-piperazinyl)pyrazine	148-154	X inactive specific transcript	Homo sapiens	7-11
31914881-0	2020	LncRNA XIST serves as a ceRNA to regulate the expression of ASF1A, BRWD1M, and PFKFB2 in kidney transplant acute kidney injury via sponging hsa-miR-212-3p and hsa-miR-122-5p.	6-chloro-2-(1-piperazinyl)pyrazine	148-154	anti-silencing function 1A histone chaperone	Homo sapiens	60-65
31914881-0	2020	LncRNA XIST serves as a ceRNA to regulate the expression of ASF1A, BRWD1M, and PFKFB2 in kidney transplant acute kidney injury via sponging hsa-miR-212-3p and hsa-miR-122-5p.	6-chloro-2-(1-piperazinyl)pyrazine	148-154	6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 2	Homo sapiens	79-85
31914881-6	2020	Specifically, 71 lncRNAs were obtained to interact with five miRNAs (hsa-miR-215-5p, hsa-miR-192-5p, hsa-miR-422a, hsa-miR-212-3p and hsa-miR-122-5p).	6-chloro-2-(1-piperazinyl)pyrazine	123-129	microRNA 1225	Homo sapiens	134-148
31914881-7	2020	Histone chaperone ASF1A (ASF1A) and bromodomain and WD repeat-containing protein 1(BRWD1) were targeted by hsa-miR-212-3p in PPI network.	6-chloro-2-(1-piperazinyl)pyrazine	115-121	anti-silencing function 1A histone chaperone	Homo sapiens	18-23
31914881-7	2020	Histone chaperone ASF1A (ASF1A) and bromodomain and WD repeat-containing protein 1(BRWD1) were targeted by hsa-miR-212-3p in PPI network.	6-chloro-2-(1-piperazinyl)pyrazine	115-121	anti-silencing function 1A histone chaperone	Homo sapiens	25-30
31914881-7	2020	Histone chaperone ASF1A (ASF1A) and bromodomain and WD repeat-containing protein 1(BRWD1) were targeted by hsa-miR-212-3p in PPI network.	6-chloro-2-(1-piperazinyl)pyrazine	115-121	bromodomain and WD repeat domain containing 1	Homo sapiens	36-82
31914881-7	2020	Histone chaperone ASF1A (ASF1A) and bromodomain and WD repeat-containing protein 1(BRWD1) were targeted by hsa-miR-212-3p in PPI network.	6-chloro-2-(1-piperazinyl)pyrazine	115-121	bromodomain and WD repeat domain containing 1	Homo sapiens	83-88
31914881-8	2020	In ceRNA network, lncRNA XIST could interact with four miRNAs (hsa-miR-212-3p, hsa-miR-122-5p, hsa-miR-215-5p, and hsa-miR-192-5p).	6-chloro-2-(1-piperazinyl)pyrazine	71-77	X inactive specific transcript	Homo sapiens	25-29
31914881-9	2020	LncRNA XIST might serve as a ceRNA to sponge hsa-miR-212-3p to regulate the development of AKI via altering the expression of ASF1A/BRWD1.	6-chloro-2-(1-piperazinyl)pyrazine	53-59	X inactive specific transcript	Homo sapiens	7-11
31914881-9	2020	LncRNA XIST might serve as a ceRNA to sponge hsa-miR-212-3p to regulate the development of AKI via altering the expression of ASF1A/BRWD1.	6-chloro-2-(1-piperazinyl)pyrazine	53-59	anti-silencing function 1A histone chaperone	Homo sapiens	126-131
31914881-9	2020	LncRNA XIST might serve as a ceRNA to sponge hsa-miR-212-3p to regulate the development of AKI via altering the expression of ASF1A/BRWD1.	6-chloro-2-(1-piperazinyl)pyrazine	53-59	bromodomain and WD repeat domain containing 1	Homo sapiens	132-137
31914881-11	2020	LncRNA XIST can serve as a ceRNA to sponge hsa-miR-212-3p and hsa-miR-122-5p to regulate AKI progression via modulating the expression of ASF1A, BRWD1, and PFKFB2.	6-chloro-2-(1-piperazinyl)pyrazine	51-57	X inactive specific transcript	Homo sapiens	7-11
31914881-11	2020	LncRNA XIST can serve as a ceRNA to sponge hsa-miR-212-3p and hsa-miR-122-5p to regulate AKI progression via modulating the expression of ASF1A, BRWD1, and PFKFB2.	6-chloro-2-(1-piperazinyl)pyrazine	51-57	anti-silencing function 1A histone chaperone	Homo sapiens	138-143
31914881-11	2020	LncRNA XIST can serve as a ceRNA to sponge hsa-miR-212-3p and hsa-miR-122-5p to regulate AKI progression via modulating the expression of ASF1A, BRWD1, and PFKFB2.	6-chloro-2-(1-piperazinyl)pyrazine	51-57	bromodomain and WD repeat domain containing 1	Homo sapiens	145-150
31914881-11	2020	LncRNA XIST can serve as a ceRNA to sponge hsa-miR-212-3p and hsa-miR-122-5p to regulate AKI progression via modulating the expression of ASF1A, BRWD1, and PFKFB2.	6-chloro-2-(1-piperazinyl)pyrazine	51-57	6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 2	Homo sapiens	156-162
31646569-0	2019	Downregulation of long non-coding RNA XIST inhibits cell proliferation, migration, invasion and EMT by regulating miR-212-3p/CBLL1 axis in non-small cell lung cancer cells.	6-chloro-2-(1-piperazinyl)pyrazine	118-124	X inactive specific transcript	Homo sapiens	38-42
31646569-9	2019	MiR-212-3p was identified as a direct target of XIST, and miR-212-3p was predicted to target CBLL1.	6-chloro-2-(1-piperazinyl)pyrazine	4-10	X inactive specific transcript	Homo sapiens	48-52
31646569-11	2019	Furthermore, CBLL1 overexpression could abolish the effects of miR-212-3p overexpression on NSCLC cell proliferation, migration, invasion and EMT in vitro.	6-chloro-2-(1-piperazinyl)pyrazine	67-73	Cbl proto-oncogene like 1	Homo sapiens	13-18
31646569-12	2019	CONCLUSIONS: XIST was significantly decreased in NSCLC tissues and cells, and XIST knockdown suppressed the proliferation, migration, invasion and EMT of NSCLC cells by miR-212-3p/CBLL1 axis.	6-chloro-2-(1-piperazinyl)pyrazine	173-179	X inactive specific transcript	Homo sapiens	78-82
31646569-12	2019	CONCLUSIONS: XIST was significantly decreased in NSCLC tissues and cells, and XIST knockdown suppressed the proliferation, migration, invasion and EMT of NSCLC cells by miR-212-3p/CBLL1 axis.	6-chloro-2-(1-piperazinyl)pyrazine	173-179	Cbl proto-oncogene like 1	Homo sapiens	180-185
31713483-0	2019	microRNA-212-3p attenuates neuropathic pain via targeting sodium voltage-gated channel alpha subunit 3 (NaV 1.3).	6-chloro-2-(1-piperazinyl)pyrazine	9-15	sodium voltage-gated channel alpha subunit 3	Rattus norvegicus	104-111
31713483-1	2019	PURPOSE: To explorer the role and potential mechanism of miR-212-3p in neuropathic pain regulation.	6-chloro-2-(1-piperazinyl)pyrazine	61-67	membrane associated ring-CH-type finger 8	Rattus norvegicus	57-60
31713483-5	2019	Besides, miR-212-3p agomir was intrathecal injected into CCI rats and expression of key apoptotic proteins were determined by western blot.	6-chloro-2-(1-piperazinyl)pyrazine	13-26	membrane associated ring-CH-type finger 8	Rattus norvegicus	9-12
31713483-6	2019	Furthermore, dual luciferase reporter assay was used to determine the binding of miR-212-3p and 3" untranslated region (3"UTR) of NaV1.3 and the expression levels of NaV1.3 were measured by western blot and RT-qPCR.	6-chloro-2-(1-piperazinyl)pyrazine	85-91	membrane associated ring-CH-type finger 8	Rattus norvegicus	81-84
31713483-8	2019	miR-212-3p were decreased in response to CCI.	6-chloro-2-(1-piperazinyl)pyrazine	4-10	membrane associated ring-CH-type finger 8	Rattus norvegicus	0-3
31713483-9	2019	Intrathecal injection of miR-212-3p agomir into CCI rats improved the PWT and PWL, decreased the IL-1beta, IL-6 and TNF-alpha, decreased the expression levels of BCL2 associated X, apoptosis regulator (Bax), cleaved caspase-3 and increased the expression levels BCL2 apoptosis regulator (Bcl-2).	6-chloro-2-(1-piperazinyl)pyrazine	29-42	membrane associated ring-CH-type finger 8	Rattus norvegicus	25-28
31713483-9	2019	Intrathecal injection of miR-212-3p agomir into CCI rats improved the PWT and PWL, decreased the IL-1beta, IL-6 and TNF-alpha, decreased the expression levels of BCL2 associated X, apoptosis regulator (Bax), cleaved caspase-3 and increased the expression levels BCL2 apoptosis regulator (Bcl-2).	6-chloro-2-(1-piperazinyl)pyrazine	29-42	interleukin 1 beta	Rattus norvegicus	97-105
31713483-9	2019	Intrathecal injection of miR-212-3p agomir into CCI rats improved the PWT and PWL, decreased the IL-1beta, IL-6 and TNF-alpha, decreased the expression levels of BCL2 associated X, apoptosis regulator (Bax), cleaved caspase-3 and increased the expression levels BCL2 apoptosis regulator (Bcl-2).	6-chloro-2-(1-piperazinyl)pyrazine	29-42	interleukin 6	Rattus norvegicus	107-111
31713483-9	2019	Intrathecal injection of miR-212-3p agomir into CCI rats improved the PWT and PWL, decreased the IL-1beta, IL-6 and TNF-alpha, decreased the expression levels of BCL2 associated X, apoptosis regulator (Bax), cleaved caspase-3 and increased the expression levels BCL2 apoptosis regulator (Bcl-2).	6-chloro-2-(1-piperazinyl)pyrazine	29-42	tumor necrosis factor	Rattus norvegicus	116-125
31713483-9	2019	Intrathecal injection of miR-212-3p agomir into CCI rats improved the PWT and PWL, decreased the IL-1beta, IL-6 and TNF-alpha, decreased the expression levels of BCL2 associated X, apoptosis regulator (Bax), cleaved caspase-3 and increased the expression levels BCL2 apoptosis regulator (Bcl-2).	6-chloro-2-(1-piperazinyl)pyrazine	29-42	BCL2, apoptosis regulator	Rattus norvegicus	162-166
31713483-9	2019	Intrathecal injection of miR-212-3p agomir into CCI rats improved the PWT and PWL, decreased the IL-1beta, IL-6 and TNF-alpha, decreased the expression levels of BCL2 associated X, apoptosis regulator (Bax), cleaved caspase-3 and increased the expression levels BCL2 apoptosis regulator (Bcl-2).	6-chloro-2-(1-piperazinyl)pyrazine	29-42	BCL2 associated X, apoptosis regulator	Rattus norvegicus	202-205
31713483-9	2019	Intrathecal injection of miR-212-3p agomir into CCI rats improved the PWT and PWL, decreased the IL-1beta, IL-6 and TNF-alpha, decreased the expression levels of BCL2 associated X, apoptosis regulator (Bax), cleaved caspase-3 and increased the expression levels BCL2 apoptosis regulator (Bcl-2).	6-chloro-2-(1-piperazinyl)pyrazine	29-42	BCL2, apoptosis regulator	Rattus norvegicus	262-286
31713483-9	2019	Intrathecal injection of miR-212-3p agomir into CCI rats improved the PWT and PWL, decreased the IL-1beta, IL-6 and TNF-alpha, decreased the expression levels of BCL2 associated X, apoptosis regulator (Bax), cleaved caspase-3 and increased the expression levels BCL2 apoptosis regulator (Bcl-2).	6-chloro-2-(1-piperazinyl)pyrazine	29-42	BCL2, apoptosis regulator	Rattus norvegicus	288-293
31713483-10	2019	The results of dual luciferase reporter assay showed miR-212-3p could directly bind with 3"UTR of NaV1.3.	6-chloro-2-(1-piperazinyl)pyrazine	57-63	membrane associated ring-CH-type finger 8	Rattus norvegicus	53-56
31713483-10	2019	The results of dual luciferase reporter assay showed miR-212-3p could directly bind with 3"UTR of NaV1.3.	6-chloro-2-(1-piperazinyl)pyrazine	57-63	sodium voltage-gated channel alpha subunit 3	Rattus norvegicus	98-104
31713483-11	2019	And the expression of NaV1.3 was up regulated in CCI rats intrathecal injected with miR-ctrl, whereas that was decreased in CCI rats intrathecal injected with miR-212-3p agomir.	6-chloro-2-(1-piperazinyl)pyrazine	163-169	sodium voltage-gated channel alpha subunit 3	Rattus norvegicus	22-28
31713483-11	2019	And the expression of NaV1.3 was up regulated in CCI rats intrathecal injected with miR-ctrl, whereas that was decreased in CCI rats intrathecal injected with miR-212-3p agomir.	6-chloro-2-(1-piperazinyl)pyrazine	163-169	membrane associated ring-CH-type finger 8	Rattus norvegicus	159-162
29548885-7	2018	Interestingly, prior injection of SB 242084 (a selective 5-HT2C antagonist) into the amygdala also blocked the MK-212 effects on OAA.	6-chloro-2-(1-piperazinyl)pyrazine	111-117	5-hydroxytryptamine (serotonin) receptor 2C	Mus musculus	57-63
26380122-2	2015	The 5-HT2C receptor agonist MK-212 applied intraperitoneally induced significant dose-dependent reduction of distance traveled in the open field test in CBA/Lac mice.	6-chloro-2-(1-piperazinyl)pyrazine	28-34	5-hydroxytryptamine (serotonin) receptor 2C	Mus musculus	4-19
29369737-7	2018	Furthermore, contractions elicited by MK-212 (5-HT2C agonist) was blocked by RS-102221 (5-HT2C antagonist), although noncompetitively.	6-chloro-2-(1-piperazinyl)pyrazine	38-44	5-hydroxytryptamine receptor 2C	Bos taurus	46-52
29369737-7	2018	Furthermore, contractions elicited by MK-212 (5-HT2C agonist) was blocked by RS-102221 (5-HT2C antagonist), although noncompetitively.	6-chloro-2-(1-piperazinyl)pyrazine	38-44	5-hydroxytryptamine receptor 2C	Bos taurus	88-94
27566488-4	2016	First, we replicated the finding that acute MK212 injection (2.0mg/kg, a highly selective 5-HT2C agonist) disrupts maternal behavior, especially on pup retrieval.	6-chloro-2-(1-piperazinyl)pyrazine	44-49	5-hydroxytryptamine receptor 2C	Rattus norvegicus	90-96
27566488-7	2016	Second, we showed that MK212 disrupts maternal behavior by specifically activating 5-HT2C receptor, as pretreatment with a 5-HT2C receptor antagonist SB242084 (0.6 and 1.0mg/kg) alleviated MK212-induced disruption on pup retrieval.	6-chloro-2-(1-piperazinyl)pyrazine	23-28	5-hydroxytryptamine receptor 2C	Rattus norvegicus	83-89
27566488-7	2016	Second, we showed that MK212 disrupts maternal behavior by specifically activating 5-HT2C receptor, as pretreatment with a 5-HT2C receptor antagonist SB242084 (0.6 and 1.0mg/kg) alleviated MK212-induced disruption on pup retrieval.	6-chloro-2-(1-piperazinyl)pyrazine	189-194	5-hydroxytryptamine receptor 2C	Rattus norvegicus	83-89
27566488-7	2016	Second, we showed that MK212 disrupts maternal behavior by specifically activating 5-HT2C receptor, as pretreatment with a 5-HT2C receptor antagonist SB242084 (0.6 and 1.0mg/kg) alleviated MK212-induced disruption on pup retrieval.	6-chloro-2-(1-piperazinyl)pyrazine	189-194	5-hydroxytryptamine receptor 2C	Rattus norvegicus	123-129
27566488-10	2016	Finally, we used c-Fos immunohistochemistry to identify the central mechanisms of the acute and repeated MK212 effects on maternal behavior.	6-chloro-2-(1-piperazinyl)pyrazine	105-110	Fos proto-oncogene, AP-1 transcription factor subunit	Rattus norvegicus	17-22
27566488-11	2016	Acute MK212 (2.0mg/kg) disrupted pup retrieval and concurrently decreased c-Fos expression in the ventral part of lateral septal nucleus (LSv), MPOA, dentate gyrus (DG) and dorsal raphe (DR), but increased it in the central amygdala (CeA).	6-chloro-2-(1-piperazinyl)pyrazine	6-11	Fos proto-oncogene, AP-1 transcription factor subunit	Rattus norvegicus	74-79
27566488-12	2016	Five days of repeated MK212 (2.0mg/kg) treatment produced a persistent disruption of pup retrieval and only decreased c-Fos expression in the DR.	6-chloro-2-(1-piperazinyl)pyrazine	22-27	Fos proto-oncogene, AP-1 transcription factor subunit	Rattus norvegicus	118-123
27059332-2	2016	The present study examined the effects of intra-dPAG infusion of the serotonin 5-HT2C receptor agonist (MK-212) in the defensive reactions and antinociception in mice with neurophatic pain confronted by a predator.	6-chloro-2-(1-piperazinyl)pyrazine	104-110	5-hydroxytryptamine (serotonin) receptor 2C	Mus musculus	79-94
26380122-5	2015	We found that the 5-HT2C receptor stimulation by MK-212 decreased distance traveled in the open field test in CBA/Lac, C57Bl/6, C3H/He, and ICR mice, whereas it failed to affect locomotor activity in DBA/2J, Asn, and Balb/c mice.	6-chloro-2-(1-piperazinyl)pyrazine	49-55	5-hydroxytryptamine (serotonin) receptor 2C	Mus musculus	18-33
25220702-7	2014	MK-212 was found to increase prolactin concentrations both in hyper- and hypoestrogenic females compared to controls (p<0.05).	6-chloro-2-(1-piperazinyl)pyrazine	0-6	prolactin	Rattus norvegicus	29-38
24275045-5	2014	The results showed that in male Wistar rats intra-BLA injection of the 5-HT2C-R agonist MK-212 facilitated inhibitory avoidance acquisition in the elevated T-maze and decreased the percentage of time spent by the animals in the lit compartment of the light-dark transition test, indicating an anxiogenic effect.	6-chloro-2-(1-piperazinyl)pyrazine	88-94	5-hydroxytryptamine receptor 2C	Rattus norvegicus	71-77